JP Morgan Chase’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-298,323
| Closed | -$16.4M | – | 7183 |
|
|
2022
Q2 | $16.4M | Buy |
+298,323
| New | +$15.7M | ﹤0.01% | 1772 |
|
|
2022
Q1 | – | Sell |
-1,300
| Closed | -$28K | – | 7264 |
|
|
2021
Q4 | $28K | Buy |
1,300
+1,200
| +1,200% | +$26.4K | ﹤0.01% | 6131 |
|
|
2021
Q3 | $2K | Buy |
+100
| New | +$2K | ﹤0.01% | 6362 |
|
|
2019
Q4 | – | Sell |
-6
| Closed | – | – | 5985 |
|
|
2019
Q3 | $0 | Sell |
6
-1,087
| -99% | -$20.8K | ﹤0.01% | 6058 |
|
|
2019
Q2 | $25K | Buy |
1,093
+992
| +982% | +$48K | ﹤0.01% | 5406 |
|
|
2019
Q1 | $7K | Buy |
+101
| New | +$6.48K | ﹤0.01% | 5591 |
|
|
2018
Q4 | – | Sell |
-3,640
| Closed | -$248K | – | 6029 |
|
|
2018
Q3 | $248K | Sell |
3,640
-1,683
| -32% | -$153K | ﹤0.01% | 4601 |
|
|
2018
Q2 | $630K | Sell |
5,323
-224
| -4% | -$22.5K | ﹤0.01% | 4075 |
|
|
2018
Q1 | $459K | Buy |
5,547
+5,541
| +92,350% | +$628K | ﹤0.01% | 4055 |
|
|
2017
Q4 | $1K | Sell |
6
-813
| -99% | -$78.1K | ﹤0.01% | 5400 |
|
|
2017
Q3 | $51K | Buy |
819
+813
| +13,550% | +$47.7K | ﹤0.01% | 4463 |
|
|
2017
Q2 | $0 | Sell |
6
-95
| -94% | -$4.85K | ﹤0.01% | 5325 |
|
|
2017
Q1 | $6K | Sell |
101
-687
| -87% | -$39.9K | ﹤0.01% | 4881 |
|
|
2016
Q4 | $47K | Sell |
788
-3,251
| -80% | -$203K | ﹤0.01% | 4573 |
|
|
2016
Q3 | $294K | Buy |
+4,039
| New | +$312K | ﹤0.01% | 3571 |
|
|
2016
Q2 | – | Sell |
-103
| Closed | -$28K | – | 5048 |
|
|
2016
Q1 | $28K | Buy |
+103
| New | +$32.9K | ﹤0.01% | 4021 |
|
Other funds holding SRRA
JP Morgan Chase's SRRA Position: Q3 2022 in Review
JP Morgan Chase sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 298,323 shares — an estimated $16.4M sold.
JP Morgan Chase first reported a position in SRRA in Q1 2016 and held it in 16 quarters. The position peaked at $16.4M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- JP Morgan Chase reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- JP Morgan Chase sold 298,323 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $16.4M.
- JP Morgan Chase first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2016 and held it in 16 quarters.
- JP Morgan Chase's Sierra Oncology, Inc. Common Stock position peaked at $16.4M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.